THURSDAY, NOVEMBER 30, 2006

6:00 p.m. – 9:30 p.m.  
Young Urologic Oncologists (Y.U.O.) Podium Presentations

Location: Hyatt-Bethesda - Haverford/Baccarat

Discussant(s): Peter Earl Clark, MD, Nashville, TN  
Jonathan Andrew Coleman, MD, Bethesda, MD  
Jeffrey Maxwell Holzbeierlein, MD, Kansas City, KS  
Daniel Wei Lin, MD, Seattle, WA  
John Francis Ward III, MD

6:30 p.m. – 7:00 p.m.  
Update on SUO long-range planning activities

Speaker: Paul Lange, MD, University of Washington

7:00 p.m. – 7:30 p.m.  
Young Urologic Oncologists (Y.U.O.) Investigator Award Presentation

Adam Kibel, MD, Washington University Medical School

7:30 p.m. – 8:45 p.m.  
Young Urologic Oncologists (Y.U.O.) Podium Presentations

Moderator: John W. Davis, MD – Eastern Virginia Medical School

7:30 p.m.  
THE HISTONE DEACETYLASE INHIBITOR FK228 IS AN EFFECTIVE TREATMENT IN A MOUSE MODEL OF HUMAN UROTHELIAL CARCINOMA (UC)

Jose Karam, MD, University of Texas Southwestern Medical Center at Dallas, Fan Jinhai, MD, University of Texas Southwestern Medical Center at Dallas, Stanfield Jennifer, University of Texas Southwestern Medical Center at Dallas, Richer Edmond, University of Texas Southwestern Medical Center at Dallas, Benaim Elie, MD, University of Texas Southwestern Medical Center at Dallas, Frenkel Eugene, MD, University of Texas Southwestern Medical Center at Dallas, Sagalowsky Arthur, MD, University of Texas Southwestern Medical Center at Dallas, Mason Ralph, PhD, University of Texas Southwestern Medical Center at Dallas and Hsieh Jer-Tsong, PhD, University of Texas Southwestern Medical Center at Dallas (Presented By: Jose Karam, MD, University of Texas Southwestern Medical Center at Dallas)

7:45 p.m.  
POLYMORPHISMS OF TGFBI AND PROSTATE CANCER PROGNOSIS

Timothy Brand, MD, Uthscsa, Carlos Bermejo, MD, Uthscsa, Dawn Garcia, MS, Uthscsa, Edith Canby-Hagino, MD, Uthscsa, Jacques Baillargeon, PhD, Uthscsa, Dean Troyer, MD, Uthscsa, Ian Thompson, MD, Uthscsa, Robin Leach, PhD, Uthscsa, And Susan Naylor, PhD, Uthscsa (Presented By: Timothy Brand, MD, Uthscsa)
8:00 p.m.  IDENTIFYING CANDIDATE TUMOR GENES ASSOCIATED WITH BLADDER CANCER INVASION AND HISTOLOGIC SUBTYPES USING OLGONUCLEOTIDE MICROARRAYS.
Theresa Koppie, MD, Memorial Sloan Kettering Cancer Center, Semra Olgac, MD, Nicholas Socci, PhD, Bernard Bochner, MD and Carlos Cordon-Cardo, MD, PhD (Presented By: Theresa Koppie, MD, Memorial Sloan Kettering Cancer Center)

8:15 p.m.  VASCULAR-TARGETED PHOTODYNAMIC THERAPY (VTP) WITH TOOKAD (WST-09) IN THE PRIMARY TREATMENT OF PROSTATE CANCER: INITIAL RESULTS
Douglas Pendsé, MB ChB MRCS, Urology Research Fellow, University College London, Caroline Moore, MB MRCS, University College London, Clare Allen, MB FRCP, University College London Hospital NHS Trust. Professor Stephen Bown, PhD FRCP, University College London and Mark Emberton, MD BS, BSc FRCS, University College London (Presented By: Douglas Pendsé, MB ChB MRCS, Urology Research Fellow, University College London)

8:30 p.m.  TARGETED TREATMENT OF LOCALIZED REGIONS OF THE PROSTATE GLAND USING MRI-GUIDED TRANSURETHRAL ULTRASOUND THERAPY: DEMONSTRATION IN VIVO
Sree Appu, MD,FRACS, Sunnybrook Hospital, University Health Network, Toronto., Rajiv Chopra, PhD, Dept Imaging Research,Sunnybrook Hospital, Laurence Klotz, MD,FRACS, Dept.Urology,Sunnybrook Hospital and Michael Bronskill, PhD, Dept Medical Imaging, Sunnybrook Hospital (Presented By: Sree Appu, MD,FRACS, Sunnybrook Hospital, University Health Network, Toronto)

8:45 p.m. – 9:30 p.m.  Y.U.O. Business Meeting

SATURDAY, DECEMBER 02, 2006

8:30 a.m. – 9:00 a.m.  Session 6 - Young Urologic Oncologists (Y.U.O.)
Moderator:  John Warren Davis, MD, Houston, TX
Discussant(s):  Jonathan Andrew Coleman, MD, Bethesda, MD
 John Francis Ward III, MD

8:30 a.m.  EFFECTS OF SHORT-TERM FINASTERIDE ON APOPTOTIC FACTORS AND ANDROGEN RECEPTORS IN PROSTATE CANCER CELLS
Robert Bass, MD, University of Kansas Medical Center, J. Brantley Thrasher, MD, Billy Perry, MD, Kattie Dennis, MD, Osama Tawfik, MD and Jeffrey Holzbeierlein, MD (Presented By: Robert Bass, MD, University of Kansas Medical Center)

8:40 a.m.  ACTIVE SURVEILLANCE OF ENHANCING RENAL TUMORS: RISK OF DISEASE PROGRESSION
Paul Crispen, MD, Fox Chase Cancer Center, Richard Greenberg, MD, Fox Chase Cancer Center, David Chen, MD, Fox Chase Cancer Center and Robert Uzzo, MD, Fox Chase Cancer Center (Presented By: Paul Crispen, MD, Fox Chase Cancer Center)